Free Trial
NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Price, News & Analysis

C4 Therapeutics logo
$2.12 +0.07 (+3.41%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.16 +0.04 (+1.89%)
As of 08/1/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About C4 Therapeutics Stock (NASDAQ:CCCC)

Key Stats

Today's Range
$1.99
$2.19
50-Day Range
$1.24
$2.42
52-Week Range
$1.09
$7.22
Volume
750,601 shs
Average Volume
1.53 million shs
Market Capitalization
$150.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Moderate Buy

Company Overview

C4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

CCCC MarketRank™: 

C4 Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 552nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    C4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    C4 Therapeutics has received no research coverage in the past 90 days.

  • Read more about C4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of C4 Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of C4 Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    C4 Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about C4 Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.73% of the outstanding shares of C4 Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    C4 Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in C4 Therapeutics has recently decreased by 17.94%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    C4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    C4 Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.73% of the outstanding shares of C4 Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    C4 Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in C4 Therapeutics has recently decreased by 17.94%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for C4 Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for CCCC on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.73% of the stock of C4 Therapeutics is held by insiders.

  • Percentage Held by Institutions

    78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about C4 Therapeutics' insider trading history.
Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CCCC Stock News Headlines

Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.
See More Headlines

CCCC Stock Analysis - Frequently Asked Questions

C4 Therapeutics' stock was trading at $3.60 at the beginning of the year. Since then, CCCC stock has decreased by 41.1% and is now trading at $2.12.

C4 Therapeutics, Inc. (NASDAQ:CCCC) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.11. The company earned $7.20 million during the quarter, compared to analyst estimates of $3.54 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 45.86% and a negative net margin of 259.60%.

C4 Therapeutics (CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

C4 Therapeutics' top institutional shareholders include Y Intercept Hong Kong Ltd (0.07%), R Squared Ltd (0.04%) and Brookstone Capital Management (0.04%).
View institutional ownership trends
.

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/07/2025
Today
8/02/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CCCC
CIK
1662579
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$4.00
Potential Upside/Downside
+466.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$105.32 million
Net Margins
-259.60%
Pretax Margin
-259.27%
Return on Equity
-45.86%
Return on Assets
-28.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.70
Quick Ratio
5.70

Sales & Book Value

Annual Sales
$35.58 million
Price / Sales
4.23
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.06 per share
Price / Book
0.69

Miscellaneous

Outstanding Shares
71,010,000
Free Float
64,808,000
Market Cap
$150.54 million
Optionable
Optionable
Beta
2.97

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CCCC) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners